Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.07 and traded as high as $0.0899. Mateon Therapeutics shares last traded at $0.0870, with a volume of 36,250 shares.
Mateon Therapeutics Stock Down 8.0%
The stock’s 50-day simple moving average is $0.09 and its 200 day simple moving average is $0.07. The company has a market cap of $7.22 million, a price-to-earnings ratio of -4.00 and a beta of 1.33.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Wall Street Stockpicker Names #1 Stock of 2026
- ALERT: Drop these 5 stocks before January 2026!
- The $650 Million Bet on AI’s Future
- Nvidia x 1,000,000
- GOLD ALERT
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
